Tramadol
Tramadol is a prescription opioid painkiller that also affects serotonin; it carries opioid overdose and dependence risk plus added risks of seizures and serotonin syndrome.
Overview
Tramadol is a prescription opioid used for moderate pain. It is often perceived as 'weaker' or safer than other opioids, but that perception is misleading: tramadol carries the standard opioid risks of dependence and respiratory depression, and it adds two dangers many other opioids don't — a lowered seizure threshold and the potential for serotonin syndrome, because tramadol also affects serotonin and norepinephrine signaling. It is widely prescribed, widely misused in some regions, and, like other opioids, can be fatal in overdose or when combined with other depressants. Its dual action makes its risk profile more complicated than its 'mild opioid' reputation suggests.
Source: MedlinePlus; DEA; PubChem CID 33741
Chemistry & mechanism of action
Tramadol has a dual mechanism. Part of its effect comes from acting (itself and through an active metabolite) on mu-opioid receptors to relieve pain, with the same class consequences of sedation, euphoria-driven reinforcement, and suppression of breathing. The other part comes from inhibiting the reuptake of serotonin and norepinephrine — similar to some antidepressants — which contributes to pain relief but also explains its distinctive added risks: it can lower the seizure threshold (making seizures more likely, especially at high doses or in combination with certain drugs) and can contribute to serotonin syndrome when combined with other serotonergic medications. As with other opioids, repeated use produces tolerance and physical dependence.
Source: MedlinePlus; PubChem CID 33741
Effects
At usual doses tramadol relieves pain and commonly causes drowsiness, dizziness, nausea, constipation, dry mouth, and sometimes a sense of calm or mild euphoria. Higher doses bring stronger sedation and the opioid danger of slowed breathing, and tramadol specifically raises the risk of seizures — which can occur even at prescribed doses in susceptible people and become more likely at high doses. Combining it with serotonergic drugs can produce serotonin syndrome (agitation, rapid heart rate, high temperature, muscle rigidity, confusion). With repeated use, tolerance and physical dependence develop, and stopping can produce both a typical opioid withdrawal and, for some, atypical withdrawal symptoms.
Source: MedlinePlus
Risks & harms
Tramadol carries the core opioid risk of respiratory depression — worsened by higher doses, reduced tolerance, and combination with other depressants such as alcohol, benzodiazepines, or other opioids — plus two added dangers: seizures (it lowers the seizure threshold, a risk in overdose and in people with seizure risk factors) and serotonin syndrome when combined with other serotonergic drugs (including many antidepressants), which can be life-threatening. Overdose can involve slowed or stopped breathing, seizures, and unconsciousness. Naloxone (Narcan) reverses the opioid component of a tramadol overdose, is available over the counter in the U.S. since 2023, and is safe to give even if opioids aren't the cause — but because tramadol also causes seizures, emergency care is still essential; give naloxone if available and call 911. Anything sold as tramadol outside a pharmacy carries the illicit-supply risk of contamination with stronger opioids such as fentanyl. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: MedlinePlus; DEA; SAMHSA
Legal status (US)
In the United States, tramadol is a Schedule IV controlled substance under the Controlled Substances Act: it has an accepted medical use and a lower abuse potential than Schedule II opioids, but it still carries a recognized risk of abuse and dependence and is available only by prescription, with limits on refills. Possessing or selling it without a valid prescription is illegal. Internationally, tramadol's status varies — it has been a significant drug of misuse in parts of Africa and the Middle East, and a number of countries control it strictly. For country-by-country legal detail, see our legality pages.
Source: DEA; UNODC
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With opioids, slowed or stopped breathing is the emergency, if available, give naloxone and call 911 immediately; it can be given while you wait for help.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 33741PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- cis-(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-olPubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C16H25NO2PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)OPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- TVYLLZQTGLZFBW-ZBFHGGJFSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- ultram, Ralivia flashtab, Ralivia ER, Tramadon, cis-Tramadol, Biomadol, Contramid, Labesfal, Tradolan, Tramadis, TramadolumPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS AND STRENGTHS Extended-release tablets are available as: 100 mg tablets: White, round shape, biconvex, beveled edge, coated tablet with release popenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Tramadol is an atypical, comparatively weak opioid for moderate pain. Unlike conventional opioids it works in two ways at once: it acts on opioid receptors and it also increases brain levels of serotonin and noradrenaline. The result is mild opioid pain relief combined with effects tied to that serotonin-boosting action. It is often perceived as "safer" than stronger opioids — a perception that can be misleading, because its second mechanism gives it dangers the others do not have.NIDA Opioids + PubChem CID 33741 ↗ · retrieved 2026-06-18
- Risks
- Tramadol's dual mechanism gives it two distinctive dangers on top of ordinary opioid effects. It lowers the seizure threshold and can trigger seizures — even at recommended amounts, and more so in overdose or in combination with other drugs. Its serotonin-boosting action can cause serotonin syndrome, especially alongside antidepressants or other serotonergic drugs. It still carries the opioid risk of respiratory depression in overdose, made worse by other depressants, and it produces tolerance and dependence. Naloxone can reverse the opioid part of an overdose, but the seizure and serotonergic effects need their own medical treatment.NIDA Opioids + PubChem CID 33741 ↗ · retrieved 2026-06-18
- Interactions
- Tramadol's approved labelling foregrounds its serotonergic risks: combining it with other serotonergic drugs — many antidepressants, triptans and others — can cause serotonin syndrome, and monoamine-oxidase inhibitors are contraindicated. Drugs that lower the seizure threshold add to its seizure risk. As with other opioids, benzodiazepines, alcohol and other CNS depressants can cause profound sedation and life-threatening respiratory depression. Because it is metabolised via CYP2D6 and CYP3A4, inhibitors and inducers of those enzymes can alter its effect and safety.DailyMed Tramadol §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 138different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 138 variants
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Schedule
- CIV
- NDC
- 71610-006 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- NuCare Pharmaceuticals,Inc.
- Schedule
- CIV
- NDC
- 68071-1671 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- NuCare Pharmaceuticals,Inc.
- Schedule
- CIV
- NDC
- 68071-4119 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- REMEDYREPACK INC.
- Schedule
- CIV
- NDC
- 70518-0942 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Coupler LLC
- Schedule
- CIV
- NDC
- 67046-1541 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; TRAMADOL HYDROCHLORIDE 37.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- St. Mary's Medical Park Pharmacy
- Schedule
- CIV
- NDC
- 60760-922 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; TRAMADOL HYDROCHLORIDE 37.5 mg/1
- Imprint
- I03
- Color
- yellow
- Shape
- OVAL
- Form
- TABLET, FILM COATED
- Labeler
- Micro Labs Limited
- Schedule
- CIV
- NDC
- 42571-119 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Advanced Rx of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0057 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 25 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Asclemed USA, Inc.
- Schedule
- CIV
- NDC
- 76420-732 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Asclemed USA, Inc.
- Schedule
- CIV
- NDC
- 76420-733 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Asclemed USA, Inc.
- Schedule
- CIV
- NDC
- 76420-734 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CIV
- NDC
- 51407-007 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- AN 627
- Color
- white
- Shape
- ROUND
- Form
- TABLET, COATED
- Labeler
- Amneal Pharmaceuticals NY LLC
- Schedule
- CIV
- NDC
- 60219-2348 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 300 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Proficient Rx LP
- Schedule
- CIV
- NDC
- 71205-569 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; TRAMADOL HYDROCHLORIDE 37.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Bryant Ranch Prepack
- Schedule
- CIV
- NDC
- 71335-1742 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- A-S Medication Solutions
- Schedule
- CIV
- NDC
- 50090-5107 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, COATED
- Labeler
- Preferred Pharmaceuticals Inc.
- Schedule
- CIV
- NDC
- 68788-8121 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Proficient Rx LP
- Schedule
- CIV
- NDC
- 82804-114 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- 101 OE
- Color
- white
- Shape
- OVAL
- Form
- TABLET, FILM COATED
- Labeler
- Cranbury Pharmaceuticals, LLC
- Schedule
- CIV
- NDC
- 27808-301 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 100 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Advanced Rx Pharmacy of Tennessee, LLC
- Schedule
- CIV
- NDC
- 80425-0108 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- A-S Medication Solutions
- Schedule
- CIV
- NDC
- 50090-5789 ↗ · 2026-06-18
- Strength
- ACETAMINOPHEN 325 mg/1; TRAMADOL HYDROCHLORIDE 37.5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Direct_Rx
- Schedule
- CIV
- NDC
- 72189-382 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 50 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- A-S Medication Solutions
- Schedule
- CIV
- NDC
- 50090-5790 ↗ · 2026-06-18
- Strength
- TRAMADOL HYDROCHLORIDE 25 mg/1
- Imprint
- A7 UpArrowhead
- Color
- white
- Shape
- ROUND
- Form
- TABLET, COATED
- Labeler
- Advagen Pharma Limited
- Schedule
- CIV
- NDC
- 72888-162 ↗ · 2026-06-18
Dosage
Pending medical reviewer
